| Predicate |
Object |
| contentType |
Journal Article|Review |
| issn |
2076-3921 |
| issueIdentifier |
2 |
| pageRange |
195- |
| publicationName |
Antioxidants (Basel, Switzerland) |
| startingPage |
195 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_6cd92d6dadb10793d606a261fe317059
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_045f64b4d6f9067fa5794d48d4938e05
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f7804975b06d277fc403b824080701fa
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0e90f5069b477398d63f03ca941d1383 |
| bibliographicCitation |
Cha SJ, Kim K. Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection. Antioxidants (Basel). 2022 Jan 20;11(2). PMID: 35204078; PMCID: PMC8868074. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4879-5207
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5263-4617 |
| date |
2022-01-20^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/35204078
https://doi.org/10.3390/antiox11020195
https://pubmed.ncbi.nlm.nih.gov/PMC8868074 |
| isPartOf |
https://portal.issn.org/resource/ISSN/2076-3921
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/44498 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6865
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4021
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10721
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10395 |